KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $346.0 million.

  • Halozyme Therapeutics' Receivables - Net rose 2110.01% to $346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.0 million, marking a year-over-year increase of 2110.01%. This contributed to the annual value of $308.5 million for FY2024, which is 3170.02% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Receivables - Net stood at $346.0 million, which was up 2110.01% from $316.3 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Receivables - Net peaked at $346.0 million during Q3 2025, and registered a low of $89.5 million during Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Receivables - Net averaged around $215.4 million, with its median value being $217.3 million (2023).
  • Per our database at Business Quant, Halozyme Therapeutics' Receivables - Net soared by 31314.67% in 2021 and then crashed by 1285.85% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Receivables - Net stood at $92.1 million in 2021, then surged by 150.85% to $231.1 million in 2022, then grew by 1.36% to $234.2 million in 2023, then surged by 31.7% to $308.5 million in 2024, then grew by 12.18% to $346.0 million in 2025.
  • Its Receivables - Net was $346.0 million in Q3 2025, compared to $316.3 million in Q2 2025 and $304.6 million in Q1 2025.